TIMP1 and carcinosarcoma: In a subsequent study, the authors verified five of the identified markers (CPN10, S100A8, PIGR, PK-M2 and AAT) and one additional marker (TIMP-1) by IHC on a tissue microarray (TMA), including 148 samples (two simple hyperplasia; eight complex hyperplasia; 39 endometrioid EC; 13 serous papillary/clear cell or Type II EC; one carcinosarcoma: 85 benign endometrium samples of which 25 proliferative, 25 secretory, 25 atrophic, and 10 menstrual).